Skip to Main Content

Author Details

Chad V Pecot
University of North Carolina at Chapel Hill
2009
68
34
PMIDPaper TitleJournal TitlePublished Year
36490372Enzymatic Macrolactamization of mRNA Display Libraries for Inhibitor Selection.ACS Chem Biol2023
37205636Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.Cancer Res2023
37141389An integrated model for predicting KRAS dependency.PLoS Comput Biol2023
35022195Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.J Immunother Cancer2022
36148399Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.Cancer Res Commun2022
34990404Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.J Clin Invest2022
32900703Targeting Epigenetics in Lung Cancer.Cold Spring Harb Perspect Med2021
33912470Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer.Front Oncol2021
33855119Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble Drugs.Bio Protoc2021
33855115Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic Agents.Bio Protoc2021
33587080Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer.Nanoscale Horiz2021
33465699RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.Lung Cancer2021
32463690Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.ACS Nano2020
31943168Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.Cancer2020
32978168A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking.Cancer Res2020
32686704Coronin 1C inhibits melanoma metastasis through regulation of MT1-MMP-containing extracellular vesicle secretion.Sci Rep2020
32596460High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma.Sci Adv2020
32493919Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Nat Commun2020
30728077Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.J Immunother Cancer2019
31559073Incidence and clinical relevance of non-small cell lung cancer lymph node micro-metastasis detected by staging endobronchial ultrasound-guided transbronchial needle aspiration.J Thorac Dis2019
31519896Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.Nat Commun2019
30918328Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.Oncogene2019
30855280Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.J Clin Invest2019
30852467Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.Cancer Treat Res Commun2019
29777108Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.Nat Commun2018
29882690Immunotherapy combinations emerging in non-small-cell lung cancer.Immunotherapy2018
29871690A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.Breast Cancer Res2018
30423298KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.Cancer Cell2018
29670528Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment.Front Pharmacol2018
29553528Incorporating Pericytes into an Endothelial Cell Bead Sprouting Assay.J Vis Exp2018
27903673Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.Clin Cancer Res2017
28403581Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.Oncotarget2017
28287740Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location.Nano Lett2017
26865225Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.Oncogene2016
27041221A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.Nat Commun2016
27064283FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.J Clin Invest2016
27036018miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.Oncotarget2016
26819345Role of Increased n-acetylaspartate Levels in Cancer.J Natl Cancer Inst2016
26700910Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.Clin Lung Cancer2016
26999601Cancer's got nerve: Schwann cells drive perineural invasion.J Clin Invest2016
26725326Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.Oncogene2016
25473001Differential platelet levels affect response to taxane-based therapy in ovarian cancer.Clin Cancer Res2015
26655797A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.Mol Syst Biol2015
26481148Erythropoietin Stimulates Tumor Growth via EphB4.Cancer Cell2015
25995442Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.J Natl Cancer Inst2015
24486585Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Clin Cancer Res2014
25490449Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.Cancer Cell2014
25281617Therapeutic silencing of KRAS using systemically delivered siRNAs.Mol Cancer Ther2014
25351418Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.Nat Commun2014
25351346Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Nat Commun2014
  • 1 - 50 of 68

Recommended Authors

Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 6
Kien Pham
Yale School of Public Health
Career Start Year 2012
Number of shared co-authors 0
Minhyung Kim
Roswell Park Comprehensive Cancer Center
Career Start Year 2010
Number of shared co-authors 1
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 6
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 2
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 8
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 6
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 5
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 2
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 3
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 14
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 5
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 6
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Career Start Year 2000
Number of shared co-authors 1
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year 1999
Number of shared co-authors 1
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 10
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 2
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 0
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1997
Number of shared co-authors 4
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 5
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 2
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 9
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 8
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 4
David M Jablons
University of California, USA Cardiovascular Research Institute san francisco
Career Start Year 1981
Number of shared co-authors 5
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 5
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 15

Collaborators

Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 34
Rajesha Rupaimoole
Harvard Medical School, Beth Israel Deaconess Medical Center
Co-authored papers 22
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Prahlad T Ram
Co-authored papers 7
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Da Yang
Co-authored papers 5
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Co-authored papers 5
Pierre P Massion
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Co-authored papers 4
Mircea Ivan
Indiana University School of Medicine
Co-authored papers 3
Bradly G Wouters
Princess Margaret Cancer Centre, University Health Network and, University of Toronto
Co-authored papers 3
Elizabeth Koch
University of Toronto
Co-authored papers 3
Andrew F Olshan
Co-authored papers 2
Yussanne Ma
Co-authored papers 2
Reanne Bowlby
Co-authored papers 2
Marco A Marra
University of British Columbia
Co-authored papers 2
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Co-authored papers 2
Hyun Seok Kim
Seoul National University
Co-authored papers 2
Steven J M Jones
University of British Columbia
Co-authored papers 2
Eric L Grogan
Veterans Affairs Tennessee Valley Healthcare System
Co-authored papers 2
Payal Sipahimalani
Co-authored papers 2
Jeroen J J P van den Beucken
Radboud University Medical Center
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Stephen A Deppen
Vanderbilt University Medical Center
Co-authored papers 2
David Cogdell
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Jacqueline E Schein
Canada British Columbia Cancer Research Centre, University of British Columbia
Co-authored papers 2
Andy Chu
Co-authored papers 2
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers 2
Wenbin Liu
Co-authored papers 2
Release 1.2